Adaptive Biotechnologies Corp. (ADPT)
25.58
-0.04
(-0.16%)
USD |
NASDAQ |
Oct 15, 16:00
25.57
-0.01
(-0.04%)
After-Hours: 20:00
Adaptive Biotechnologies Research and Development Expense (Quarterly) : 18.30M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.30M |
| March 31, 2026 | 20.89M |
| December 31, 2025 | 19.89M |
| September 30, 2025 | 20.92M |
| June 30, 2025 | 21.50M |
| March 31, 2025 | 21.50M |
| December 31, 2024 | 21.28M |
| September 30, 2024 | 22.13M |
| June 30, 2024 | 22.99M |
| March 31, 2024 | 27.93M |
| December 31, 2023 | 23.78M |
| September 30, 2023 | 23.20M |
| June 30, 2023 | 27.01M |
| March 31, 2023 | 27.60M |
| December 31, 2022 | 26.36M |
| September 30, 2022 | 30.70M |
| Date | Value |
|---|---|
| June 30, 2022 | 32.26M |
| March 31, 2022 | 33.20M |
| December 31, 2021 | 30.28M |
| September 30, 2021 | 32.54M |
| June 30, 2021 | 35.32M |
| March 31, 2021 | 31.52M |
| December 31, 2020 | 33.91M |
| September 30, 2020 | 28.60M |
| June 30, 2020 | 23.76M |
| March 31, 2020 | 22.30M |
| December 31, 2019 | 19.54M |
| September 30, 2019 | 19.17M |
| June 30, 2019 | 15.60M |
| March 31, 2019 | 11.75M |
| June 30, 2018 | 9.008M |
| March 31, 2018 | 8.421M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Personalis, Inc. | 16.34M |
| 10X Genomics, Inc. | 56.79M |
| Alamar Biosciences, Inc. (California) | 13.82M |
| Champions Oncology, Inc. | 2.344M |
| Medpace Holdings, Inc. | -- |